(VIANEWS) - Pfizer (PFE), SunPower Corporation (SPWR), Bank of Marin Bancorp (BMRC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Pfizer (PFE)
108.8% sales growth and 14.03% return on equity
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide.
Pfizer's sales growth this year is anticipated to be 91.3% and a negative 12.9% for next year.
Year-on-year quarterly revenue growth grew by 44.6%, now sitting on 46.41B for the twelve trailing months.
Volume
Today's last reported volume for Pfizer is 25043000 which is 36.62% below its average volume of 39515300.
Pfizer's sales growth for the next quarter is 108.8%. The company's growth estimates for the ongoing quarter and the next is 50% and 150%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.03%.
Volatility
Pfizer's last day, last week, and last month's current intraday variation average was 2.09%, 1.95%, and 6.46%, respectively.
Pfizer's highest amplitude of average volatility was 3.02% (day), 3.83% (last week), and 4.39% (last month), respectively.
Pfizer's Stock Yearly Top and Bottom Value
Pfizer's stock is valued at $58.33 at 15:22 EST, way higher than its 52-week high of $51.86.
Pfizer's Moving Average
Pfizer's worth is way higher than its 50-day moving average of $43.57 and way higher than its 200-day moving average of $42.49.Previous days news about Pfizer(PFE)
- According to FXStreet on Wednesday, 22 December, "Joe Manchin's opposition of the climate and social spending bill." This joins with the Bloomberg news that the US Food and Drug Administration (FDA) is up for authorizing a pair of pills from Pfizer and Merck to treat Covid-19 as soon as this week to favor risk-on mood. "
- According to FXStreet on Wednesday, 22 December, "Further, in the middle of Wall Street's session, the US Food and Drug Administration (FDA) is set to approve Covid-19 treatment pills, developed by Pfizer and Merck."
- According to FXStreet on Wednesday, 22 December, "Furthermore, news that the US Food and Drug Administration (FDA) is up for authorizing a pair of pills from Pfizer and Merck to treat Covid-19 as soon as this week, per Bloomberg's sources, also underpinned the risk-on mood."
- According to Business Insider on Wednesday, 22 December, "Meanwhile, media reports suggest that the U.S. Food and Drug Administration could authorize two Covid-19 pills from Pfizer Inc. and Merck & Co. Inc. as soon as this week."
2. SunPower Corporation (SPWR)
38.2% sales growth and 225.67% return on equity
SunPower Corporation delivers solar solutions worldwide.
SunPower Corporation's sales growth this year is expected to be 28.9% and 25.5% for next year.
Year-on-year quarterly revenue growth grew by 41.9%, now sitting on 1.23B for the twelve trailing months.
Volume
Today's last reported volume for SunPower Corporation is 1398410 which is 63.58% below its average volume of 3840010.
SunPower Corporation's sales growth for the next quarter is 38.2%. The company's growth estimates for the current quarter and the next is 225% and 42.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 225.67%.
Volatility
SunPower Corporation's last day, last week, and last month's current intraday variation average was 0.83%, 3.49%, and 3.88%, respectively.
SunPower Corporation's highest amplitude of average volatility was 4.02% (day), 4.54% (last week), and 6.37% (last month), respectively.
SunPower Corporation's Stock Yearly Top and Bottom Value
SunPower Corporation's stock is valued at $20.69 at 15:22 EST, way below its 52-week high of $57.52 and above its 52-week low of $19.34.
SunPower Corporation's Moving Average
SunPower Corporation's worth is way below its 50-day moving average of $28.20 and way under its 200-day moving average of $26.12.3. Bank of Marin Bancorp (BMRC)
21.2% sales growth and 7.75% return on equity
Bank of Marin Bancorp operates as the holding company for Bank of Marin that provides a range of financial services primarily to professionals, small and middle-market businesses, individuals, and not-for-profit organizations in San Francisco Bay Area, California in the United States.
Bank of Marin Bancorp's sales growth this year is anticipated to be 8.5% and 11.9% for next year.
Year-on-year quarterly revenue growth grew by 18.7%, now sitting on 111.87M for the twelve trailing months.
Volume
Today's last reported volume for Bank of Marin Bancorp is 276282 which is 513.48% above its average volume of 45035.
Bank of Marin Bancorp's sales growth for the next quarter is 21.2%. The company's growth estimates for the ongoing quarter and the next is a negative 6.7% and negative -16.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.75%.
Volatility
Bank of Marin Bancorp's last day, last week, and last month's current intraday variation average was 0.91%, 0.48%, and 1.48%, respectively.
Bank of Marin Bancorp's highest amplitude of average volatility was 6.21% (day), 3.40% (last week), and 3.04% (last month), respectively.
Bank of Marin Bancorp's Stock Yearly Top and Bottom Value
Bank of Marin Bancorp's stock is valued at $36.72 at 15:22 EST, way under its 52-week high of $42.19 and way higher than its 52-week low of $30.69.
Bank of Marin Bancorp's Moving Average
Bank of Marin Bancorp's worth is under its 50-day moving average of $37.34 and above its 200-day moving average of $36.07.4. Brown & Brown (BRO)
16.4% sales growth and 14.92% return on equity
Brown & Brown, Inc. markets and sells insurance products and services in the United States, England, Canada, Bermuda, and the Cayman Islands.
Brown & Brown's sales growth this year is expected to be 16.1% and 7.6% for next year.
Year-on-year quarterly revenue growth grew by 14.3%, now sitting on 2.95B for the twelve trailing months.
Volume
Today's last reported volume for Brown & Brown is 430330 which is 79.67% below its average volume of 2117230.
Brown & Brown's sales growth for the next quarter is 16.4%. The company's growth estimates for the ongoing quarter and the next is 21.9% and 4.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.92%.
Volatility
Brown & Brown's last day, last week, and last month's current intraday variation average was 0.39%, 0.85%, and 1.10%, respectively.
Brown & Brown's highest amplitude of average volatility was 2.09% (day), 1.65% (last week), and 1.95% (last month), respectively.
Brown & Brown's Stock Yearly Top and Bottom Value
Brown & Brown's stock is valued at $66.32 at 15:22 EST, below its 52-week high of $67.91 and way higher than its 52-week low of $42.72.
Brown & Brown's Moving Average
Brown & Brown's worth is higher than its 50-day moving average of $63.72 and way above its 200-day moving average of $55.31.5. Balchem Corporation (BCPC)
9.4% sales growth and 10.92% return on equity
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally.
Balchem Corporation's sales growth this year is expected to be 10.7% and 6.4% for next year.
Year-on-year quarterly revenue growth grew by 13%, now sitting on 766.6M for the twelve trailing months.
Volume
Today's last reported volume for Balchem Corporation is 453447 which is 291.09% above its average volume of 115943.
Balchem Corporation's sales growth for the next quarter is 9.4%. The company's growth estimates for the current quarter and the next is 13.3% and 16.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.92%.
Volatility
Balchem Corporation's last day, last week, and last month's current intraday variation average was 1.16%, 1.16%, and 1.42%, respectively.
Balchem Corporation's highest amplitude of average volatility was 2.81% (day), 2.44% (last week), and 2.38% (last month), respectively.
Balchem Corporation's Stock Yearly Top and Bottom Value
Balchem Corporation's stock is valued at $165.07 at 15:22 EST, below its 52-week high of $174.29 and way higher than its 52-week low of $106.29.